Sunovion Pharmaceuticals Inc. And Takeda Announce Results From A New Study Showing Maintenance Treatment With Lurasidone Reduced The Risk Of Relapse In Adults With Schizophrenia

Published: Mar 03, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MUNICH--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (“Sunovion”) (Head Office: Marlborough, Massachusetts) and Takeda Pharmaceutical International GmbH ("Takeda") (Zurich, Switzerland) today announced the results from a double-blind, placebo-controlled study that evaluated the efficacy, safety and tolerability of lurasidone for the maintenance treatment of adults with schizophrenia. Lurasidone is a once-daily oral atypical antipsychotic indicated for the treatment of adults with schizophrenia and is currently available in the United States, Canada and Switzerland. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a Positive Opinion for lurasidone for the treatment of schizophrenia in adults on January 23, 2014.

Help employers find you! Check out all the jobs and post your resume.

Back to news